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INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a
curative therapy for some hematologic malignancies,
immune disorders, and genetic diseases. Despite intensive
conditioning regimens, HSCT may fail because of either
relapse of the malignancy or rejection of the graft. A second
HSCT may be clinically indicated in some patients whose
initial HSCT failed.
Approximately 20% to 60% of patients who undergo
transplantation for hematologic malignancies relapse after
HSCT [1,2]. The management of relapsed patients follow-
ing HSCT is controversial. The results of chemotherapy
alone following HSCT, especially for pediatric acute lym-
phoblastic leukemia (ALL), have been disappointing, and
this treatment rarely results in a cure [3,4]. The results of
newer therapies, such as donor lymphocyte infusions [5,6],
have also been disappointing. Previous studies have reported
disease-free survival rates of 7% to 38% for patients with
ALL following a second HSCT [6-9].
Graft failure occurs most frequently in patients with an
intact immune system who receive hematopoietic stem cells
(HSC) from either unrelated bone marrow or cord blood.
Primary or secondary graft failure has occurred in 14% of
recipients of unrelated HSCT [10]. Furthermore, approxi-
mately 50% of recipients of unrelated cord blood trans-
plants who have an intact immune system do not have sus-
tained donor hematopoiesis [11]. Previous reports have
shown a 17% to 44% disease-free survival rate for patients
receiving a second HSCT for graft failure. Most series have
studied patients with intact immune systems, such as those
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ABSTRACT
Despite potent intensive conditioning regimens, hematopoietic stem cell transplantation (HSCT) may fail because
of either relapse of the malignancy or the rejection of the graft. We report on 27 pediatric patients who received a
second HSCT from an allogeneic donor for relapsed malignancy or graft failure. One-year, 5-year, and 10-year
probabilities of survival for all patients were 53%, 36%, and 24%, respectively. Twenty patients received second
HSCTs for relapsed malignancy, of whom 6 were alive and disease free at the time of this report. Seven patients
received a second HSCT for graft failure, of whom 3 were alive and well as of this report. Twenty-five patients
were tested for immune reconstitution following their second HSCT. Sixteen patients developed antigen-specific
T-lymphocyte responses; the median time to development of antigen-specific responses was 13 months. There was
no significant neurocognitive decline in patients tested 1 to 3 years following their second HSCT. Endocrine
evaluations revealed deficiencies in growth hormone (7 patients), gonadal function (3 patients), and thyroid func-
tion (2 patients). Three patients developed significant abnormalities of tooth development, including absence of
secondary teeth. These results show that a second HSCT offers curative therapy for selected pediatric patients
whose first HSCT failed. Although toxicity is considerable following a second transplantation, the major causes of
mortality continue to be relapse and infection.
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with severe aplastic anemia and thalassemia. Grandage et al.
examined 12 patients with graft failure following first
HSCT. Two thirds of these patients initially underwent
transplantation for leukemia. Of these 12 patients, 5 were
alive with a median survival of 38 months; however, only 2
of these patients remained disease free [12-14].
We report on 27 pediatric patients who suffered either
relapse or graft failure after their ﬁrst HSCT and received a
second transplant from an allogeneic donor. We describe
their clinical outcomes in terms of immune reconstitution,
endocrine dysfunction, skeletal deformities, neurocognitive
function, and secondary malignancies. Nine of the 27 patients
were alive and well at the time of this report, suggesting that a
second HSCT is indicated in selected pediatric patients
whose ﬁrst HSCT fails.
PATIENTS AND METHODS
Informed Consent
The Committee on Clinical Investigation (Institutional
Review Board) of Childrens Hospital Los Angeles reviewed
and approved the protocols for initial HSCT, second
HSCT, and long-term follow-up studies. All patients were
recruited for long-term follow-up studies after informed
consent was obtained for their participation in the respective
HSCT studies.
Patients
Between September 1985 and January 2001, 27 pediatric
patients with ALL (n = 11), acute myeloblastic leukemia
(AML, n = 3), severe combined immunodeﬁciency (SCID,
n = 3), natural killer (NK) cell leukemia (n = 2), myelodys-
plastic syndrome (MDS, n = 2), juvenile monomyelogenous
leukemia (JMML, n = 2), chronic myelogenous leukemia
(CML, n = 1), non-Hodgkin’s lymphoma (NHL, n = 1), pure
red cell aplasia (n = 1), or hemophagocytic lymphohistiocyto-
sis (HLH, n = 1) received second HSCTs. Nineteen patients
were boys and 8 were girls. Patient characteristics are shown
in Table 1. Patients are identified by their unique patient
number (UPN).
Twenty patients received second HSCT for relapse of
hematologic malignancy. For these patients, second trans-
plantations occurred between 4 months and 6 years (median,
13 months) following their ﬁrst HSCT. These 20 patients
achieved remission prior to receiving their second HSCT.
Seven patients received second HSCT for graft failure,
either primary or secondary. Second transplantations for
graft failure were performed between 5 weeks and 17 months
(median, 3 months) following the ﬁrst transplantation.
The median age of all recipients at the time of their ﬁrst
HSCT was 4 years (range, 4 months to 15 years), and their
median age at the time of their second HSCT was 6 years
(range, 8 months to 15 years).
Pre-HSCT Conditioning Regimens
Preparative regimens and donors for HSCT for the ﬁrst
and second HSCT are shown in Tables 1 and 2. Eighteen
patients received related histocompatible HSCTs for both
their ﬁrst and second HSCT. Of the remaining 9 patients,
7 patients received HSCT from alternative donors (unrelated
or haploidentical) for both their first and second HSCTs;
4 patients received the same alternative donor product;
2 patients received an autologous HSCT followed by a
matched unrelated donor (MUD) HSCT; 2 patients received
an unrelated peripheral blood stem cell transplant from the
same donor for their second HSCT; and 1 patient received a
haploidentical HSCT following an unrelated cord blood
transplantation (UCBT). For their ﬁrst HSCT, 22 patients
received busulfan, 16 mg/kg or, for those younger than
5 years, 640 mg/m2, and cyclophosphamide, 200 mg/kg. The
remaining 5 patients received alternative regimens shown in
Table 2. For their second transplantation, 20 patients
received total body irradiation (TBI) (1200 cGy, 200 Gy
twice a day for 3 days) and etoposide (VP-16), 60 mg/kg.
The remaining patients received alternative preparative regi-
mens shown in Table 2.
Graft-versus-host disease (GVHD) prophylaxis consisted
of methotrexate (MTX), 10 mg/m2 on days +3, +6, +11, and
+18. Cyclosporin (CSA) was also given to those patients who
were older than 10 years and/or whose donors were older
than 10 years. Recipients of unrelated HSCT received
antithymocyte globulin (ATG) for 7 doses, on alternate days,
beginning on day +5. Two patients, both of whom had
SCID, received T-cell–depleted haploidentical HSCT fol-
lowed by ATG and methylprednisolone. For the second
HSCT, 26 patients received GVHD prophylaxis with CSA
and MTX. One patient (UPN 447) received MTX only for
GVHD prophylaxis during the second transplantation.
Patients who developed GVHD received corticosteroids as
first-line GVHD therapy. Patients who remained on CSA
also received monthly intravenous immune globulin (IVIG)
replacement therapy.
Immune Reconstitution
Both cellular and humoral immunological functions were
determined following the second HSCT. Patient immune
function was evaluated by determining the antigen-speciﬁc
T-lymphocyte blastogenesis following specific antigenic
stimulation (tetanus toxoid, Candida, cytomegalovirus
[CMV], herpes simplex virus [HSV], and varicella zoster
virus [VZV]) as previously described [15]). Positive responses
were defined as a ∆cpm ≥ 3000. Antibodies to polyribose
phosphate (PRP) were measured by an enzyme-linked
immunosorbent assay (ELISA) as previously described [16].
Long-term Follow-up
Patients who survived more than 1 year following their
HSCT and remained in remission were evaluated in a long-
term follow-up study. Patients who underwent transplanta-
tion prior to 1993 did not have pre-HSCT testing performed
and were therefore not eligible for the present analysis.
Patients who were not being treated with clonidine for
hypertension had assessment of the growth hormone axis
with clonidine stimulation. Abnormal responses were
defined as <10 ng/mL after oral clonidine. Levels of free
thyroxine, thyroid-stimulating hormone, luteinizing hor-
mone (LH), follicle-stimulating hormone (FSH), and estra-
diol or testosterone were measured to assess thyroid and
gonadal function. Elevated LH and FSH levels for age were
considered evidence of primary gonadal failure. Patients
were routinely assessed for dental abnormalities and the
presence of avascular necrosis of the bone (AVN).
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Neurocognitive Function
Prior to their ﬁrst HSCT, most patients were evaluated
to determine their neurocognitive function. One to 2 years
following their second HSCT, patients were reevaluated.
Tests were administered in the patient’s primary language,
either English or Spanish. Domains that were evaluated
included overall cognitive/intellectual functioning, verbal
skills, performance skills, and receptive vocabulary.
Table 1. Patient Characteristics*
Cause of Time Conditioning Conditioning Donor for
Patient Second Between Regimen of Donor for Regimen of Second 
UPN Age† Sex Diagnosis HSCT HSCTs First HSCT First HSCT Second HSCT HSCT Status
11 5 y M Pure red Primary graft 2 mo Bu/Cy/TLI/ 6/6 sibling Bu/Cy/TLI/pro- Same Alive and
cell aplasia failure procarba- carbazine/ATG well
zine/ATG
29 9 y M NHL Relapse 4 mo TBI/VP-16/ 6/6 sibling TBI/VP-16/ARA-C Same Died, PD
ARA-C
103 6 y M ALL CR2 Relapse 6 y Bu/Cy 6/6 sibling TBI/VP-16 Same Died, 
GVHD
184 7 y F ALL CR2 Relapse 6 y Bu/Cy 6/6 sibling TBI/VP-16 Same Died, sepsis/ 
GVHD
188 9 mo F Infant ALL Relapse 8 mo Bu/Cy 6/6 MUD TBI/VP-16 Same Died, second  
(BM) tumor
214 3 y M Mixed lineage Relapse 26 mo Bu/Cy Auto TBI/VP-16 6/6 MUD Alive and 
ALL (BM) well
250 7 y M MDS mono- Relapse 36 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Died, GVHD
somy 7
274 4 y F AML Relapse 32 mo Bu/Cy Auto TBI/VP-16 6/6 MUD Alive and
(BM) well
334 13 y F NK cell Relapse 12 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Alive and
leukemia well
364 10 y F CML Relapse 10 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Alive and 
well
382 9 mo F Bare Primary graft 6 mo Bu/Cy/ATG Haplo- Bu/Cy/ATG Same Died, graft 
Lymphocyte failure identical failure
Syndrome (mother)
386 12 y M AML CR2 Relapse 7 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Alive and 
well
399 18 mo M JMML Primary graft 3 mo Bu/Cy/ATG 6/6 MUD TBI/VP-16 Same Died, PD 
failure (BM)
402 10 y M T-ALL CR2 Relapse 20 mo Bu/Cy 6/6 sibling TBI/VP-16/ARA-C Same Died, PD
411 14 mo M HLH Secondary 18 mo Bu/Cy/VP-16/ 6/6 MUD TBI (sparing head Same Alive and
graft failure ATG (BM) and neck)/Cy well
434 2 y F SCID/NHL Primary graft 1 mo Cy/ATG 6/6 mother TBI/VP-16/Cy/ Same Died, PD 
failure ARA-C
447 3 y M AML CR2 Relapse 4 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Died, PD
450 16 mo M ALL, mono- Relapse 13 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Died, PD
somy 7
453 8 y M ALL CR2 Relapse 10 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Alive and 
well
461 18 mo M JMML Relapse 19 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Died, PD
464 9 y F ALL CR2 Relapse 16 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Died, PD
477 4 y M Ph+ ALL Relapse 4 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Died, PD
308 51/2 y F ALL CR2 Relapse 10 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Died, PD
562 5 mo M SCID Primary graft 3 mo Bu/Cy/ATG 4/6 UCBT Bu/Cy/ATG Haplo- Alive and
failure identical well
(mother)
622 3 y M MDS Relapse 8 mo Bu/Cy/ATG 6/6 MUD TBI/VP-16 Same Died, PD
(BM) donor
PBSC
660 15 y M NK cell Primary graft 2 mo TBI/VP-16 6/6 MUD Fludarabine/ Same Died, sepsis/ 
leukemia failure (BM) Cy/TLI donor organ
PBSC toxicity
561 101/2 y M ALL CR2 Relapse 27 mo Bu/Cy 6/6 sibling TBI/VP-16 Same Died, GVHD
*Bu indicates busulfan; Cy, cyclophosphamide; TLI, total lymphoid irradiation; ARA-C, cytarabine; PD, progressive disease; CR, complete
remission; Auto, autologous; Ph, Philadelphia chromosome; PBSC, peripheral blood stem cells.
†Age at ﬁrst HSCT.
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Statistical Analysis
The probability of event-free survival was calculated by
Kaplan-Meier analysis [17]. Data on patients were censored at
the ﬁrst adverse event: death due to treatment-related toxicity,
graft failure, relapse, or other causes. Paired Student t tests
were used for statistical analysis of the neurocognitive tests.
RESULTS
Outcome of HSCT for the Primary Disease
Kaplan-Meier analysis of the probability of event-free
survival following a second HSCT is shown for patients
with either relapsed malignancies or graft failure (Figure 1).
One-year, 5-year, and 10-year probabilities of survival for all
patients were 53%, 36%, and 24%, respectively. At the time
of this report, 9 of the 27 patients who received a second
HSCT were alive and disease free and 6 of the 20 patients
who received a second HSCT for relapsed malignancy were
alive and disease free. Causes of death for the study patients
were relapse (9 patients), sepsis/toxicity (2 patients), acute
GVHD (2 patients), and secondary malignancy (1 patient).
Of the 7 patients who received a second HSCT for graft
failure, 3 (43%) were alive as of this report. Causes of death
for the other 4 patients included relapse (2), sepsis (1), and
graft failure (1).
Eleven patients developed clinically detectable GVHD.
Five patients had grade 3 to 4 acute GVHD, and 6 patients
developed chronic GVHD. First-line therapy for acute
GVHD was corticosteroids. Patients who developed
steroid-nonresponsive acute GVHD required intensive
immunosuppressive therapy with other agents, including
ATG, tacrolimus, and daclizumab.
Immune Reconstitution
The immune reconstitution of 25 patients was longitu-
dinally evaluated following their second HSCT. The
remaining 2 patients died too early to be evaluated. Of the
25 patients tested, 16 (64%) developed antigen-specific
responses following HSCT. The median time to the devel-
opment of their ﬁrst antigen-speciﬁc response was 13 months
(range, 3-34 months). The remaining 9 patients did not
develop antigen-specific T-lymphocyte proliferative
responses within follow-up periods of 34 months or less.
Following their second HSCT, 16 patients were evalu-
ated for their response to a naturally occurring bacterial car-
bohydrate, Polyribose phosphate (PRP) the capsular antigen
of Hemophilus inﬂuenzae. PRP testing was not performed
on patients receiving IVIG therapy. Because patients receiv-
ing CSA remained on IVIG, these patients were not evalu-
ated for their response to PRP. Only 3 patients had normal
PRP responses (defined as a value >100 ng/mL). Eight
patients developed subnormal PRP responses (15-100
ng/mL) at an average of 21 months (range, 3-46 months)
following their second HSCT. Eight patients did not
develop any PRP antibody response following their second
HSCT. The 3 patients who had normal PRP levels all
received histocompatible HSCT from a HLA-matched sib-
lings. None of the patients who received a MUD HSCT
developed normal PRP antibody responses.
Endocrine Function
The patients who survived more than 1 year following
their second HSCT and were on minimal or no steroid ther-
apy received long-term endocrine evaluations. The results
are summarized in Table 3. The most signiﬁcant abnormali-
ties were growth hormone (GH) deﬁciency (7 of 11 patients
tested), primary gonadal insufﬁciency (3 of 6 patients), and
hypothyroidism, either primary or central (2 of 11 patients).
Of the 7 patients who developed GH deﬁciency, 2 patients
were receiving GH replacement as of this report. One
patient died prior to initiation of GH replacement therapy.
Of the remaining 4 patients, 3 patients remained below the
mean for height but were within 2 standard deviations for
age as of this report. The fourth patient (UPN 411) was
too young to begin GH therapy. One patient (UPN 188)
began GH replacement but developed an osteosarcoma
within 1 year.
Figure 1. Kaplan-Meier probability of disease-free survival for
patients receiving a second HSCT for graft failure ( ) and
relapsed malignancy ( ).
Table 2. Transplantation-Related Data
HSCT No. 1, n HSCT No. 2, n
Donor
Autologous 2 0
Histocompatible 18 18
Haploidentical 1 2
Matched unrelated BM 5 5
Matched unrelated PBSC 0 2
Matched unrelated cord blood 1 0
Preparative regimen
Bu/Cy 22 1
Bu/Cy/VP-16 1 0
Bu/Cy/procarbazine/TLI 1 1
Bu/Cy/TBI 0 1
TBI/VP-16 1 19
TBI/Cy 0 1
TBI/VP-16/ARA-C 1 2
TBI/VP-16/Cy/ARA-C 0 1
Cy only 1 0
Fludarabine/Cy/TLI 0 1
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Three patients had evidence of primary gonadal dys-
function (ovarian 2, testicular 1). The 2 female patients with
ovarian insufﬁciency (UPN 334 and 364) received their ﬁrst
HSCT at the ages of 13 years and 10 years, respectively, and
their second HSCT at the ages of 14 and 11 years, respec-
tively. The male patient with testicular insufﬁciency (UPN
214) had his ﬁrst HSCT at the age of 3 years and his second
HSCT at the age of 5 years. All 3 patients received busul-
fan/cytoxan as their first conditioning regimen and
TBI/VP-16 for their second HSCT. As of this report, the
female patients remained on estrogen/progestin replace-
ment, and the male patient was receiving GH therapy prior
to the planned institution of testosterone replacement.
Two patients developed central hypothyroidism. One
patient (UPN 214) was receiving thyroid hormone replace-
ment as of this report, and the remaining patient (UPN 103)
died of pulmonary complications.
One patient (UPN 274) developed insulin-dependent
diabetes mellitus 6 years after her second HSCT. Her post-
transplantation course was complicated by mild skin
GVHD. Her other complications included GH deficiency
and hypothyroidism. There is no known family history of
diabetes, and her MUD donor’s diabetes status is unknown.
Skeletal and Dental
Two patients (UPN 334 and 364) who received related
histocompatible second HSCT developed AVN of the hips
and required subsequent unilateral hip replacements. Both
of these patients had signiﬁcant GVHD and received pro-
longed steroid therapy. GVHD resolved in both patients,
and steroid therapy was discontinued. However, both
patients continued to have pain in other large joints.
Three patients (UPN 188, 214, and 411) had severe
dental abnormalities, including absence of secondary teeth
and microdontia. The dental x-ray of 1 patient (UPN 214)
is shown in Figure 2. UPN 214 and 411 were undergoing
evaluation for dental implants and restorations as of this
report. UPN 188 had minimal dental restorations prior to
developing a secondary malignancy.
Neurocognitive Function
Neurocognitive functioning was evaluated prior to the
ﬁrst HSCT and at 1 to 3 years following the second HSCT.
Pre-HSCT evaluations were performed on patients within
1 month of hospital admission for HSCT. The overall neu-
rocognitive function mean score was 87 (pre–initial HSCT)
versus 72.8 (post–second HSCT) (P = .13, n = 6). When
pre–initial-HSCT scores were compared to the post–second-
HSCT scores, there were also decreases in both mean ver-
bal and performance skills scores; however, these decreases
were not signiﬁcant (verbal skills decreased from 96.5 [pre]
to 89.75 [post], P = .57, n = 4; performance scores decreased
Table 3. Results of Long-term Follow-up
No. Affected* No. Tested
GH 7 11
Gonadal function
Ovarian 2 6
Testicular 1
Thyroid 2 11
GVHD
Skin 11
Gastrointestinal 4
Lungs 4
Liver 1
AVN 2
Abnormal tooth development 3
Secondary malignancy 1
*Of the 27 patients who received a second HSCT.
Figure 2. Dental panographic x-ray of patient UPN 214 obtained 7 years post–second HSCT. The black arrows point to the areas of microdontia,
the bilateral upper second molars, and the lower right second molar. The white arrows represent absent secondary teeth at the lower second premo-
lar (the bicuspid) and the third molar.
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from 88.4 [pre] to 84.2 [post], P = .69, n = 5). In contrast,
receptive vocabulary scores increased from 89.3 to 99.3 (P =
.46, n = 3). The neurocognitive tests are age based; therefore
because of their age some children did not receive speciﬁc
tests. Consequently, the numbers of patients tested in each
of the neurocognitive domains differed.
Secondary Malignancy
Patient UPN 188 developed a secondary malignancy
(osteosarcoma) 6 years following her second transplantation
for infantile ALL. This patient received her ﬁrst HSCT at
the age of 9 months and the second HSCT at the age of
17 months (Figure 3). Her conditioning regimen for the
ﬁrst HSCT consisted of busulfan and cytoxan and that for
her second HSCT consisted of TBI (1200 Gy) and VP-16
(60 mg/kg). She developed a secondary malignancy 1 year
after initiation of GH replacement therapy. She died of pro-
gressive osteosarcoma.
DISCUSSION
Relapse and graft failure following HSCT are devastating
complications with high mortality rates. Our analysis of
27 pediatric patients who underwent second HSCTs shows
that the probability of 10-year event-free survival is 24%.
The majority of our patients received a non–TBI-based regi-
men for their ﬁrst HSCT. Previous studies have shown simi-
lar survival rates for patients receiving TBI-based regimens
for their ﬁrst HSCT [7,8]. It might be expected that a longer
interval between ﬁrst and second HSCT might result in a
better outcome because patients would then have a longer
period to recover from the toxic effects of the ﬁrst HSCT.
Seventeen patients with relapsed leukemia received their sec-
ond HSCT more than 6 months following their ﬁrst HSCT;
7 of these patients were alive and disease free as of this report.
Of the patients who received their second HSCT for relapsed
malignancy less than 6 months following their ﬁrst HSCT,
1 of 3 remained alive and disease free. These numbers are too
small to be the basis of any meaningful conclusions.
In our series of pediatric patients receiving second trans-
plantations for graft failure, at the time of this report 3 of
7 patients were alive following their second HSCT. Of note,
UPN 562 developed graft failure following HSCT with unre-
lated cord blood that was later found to have been obtained
from a donor with a chromosomal abnormality (XXY). This
patient subsequently underwent another transplantation with
a haploidentical HSCT and was alive and well as of this
report [18]. Overall, our results are comparable to previous
results of second transplantations for graft failure.
It might be expected that the recipients of 2 HSCT
would have more transplantation-related side effects than
would the recipients of only 1 HSCT. Eleven of the second-
HSCT recipients developed acute and/or chronic GVHD.
Five patients developed severe (grade 3 or 4) acute GVHD.
Sixteen patients did not develop any GVHD with either
HSCT. Thus, a second HSCT does not increase the likeli-
hood of developing GVHD.
GVHD and its therapies are associated with immune
deﬁciency in HSCT recipients. Recipients of HSCT are at
increased risk of bacterial and viral infections, suggesting
defects in both humoral and cellular immunity. Weinberg
et al. have reported that GVHD is the major cause of defec-
tive thymopoiesis after HSCT. Cytotoxic therapy may
adversely impact thymopoietic function [19-21]. We evalu-
ated the impact of a second myeloablative conditioning regi-
men on recipient immune function. Sixteen (67%) of
24 patients developed antigen-speciﬁc responses at a median
of 13 months from their second HSCT, whereas 8 patients
did not develop any antigen-speciﬁc responses within a maxi-
mum follow-up period of 34 months. Other investigators
have shown that a T-lymphocyte proliferative response to
HSV can be detected in HSV-positive HSCT recipients as
early as 40 days following HSCT and that this response is
followed by the acquisition of responses to VZV and CMV
[22]. Routine acyclovir is known to delay the appearance of
T-lymphocyte proliferative responses by inhibiting viral reac-
tivation [22,23]. Because all of the herpes virus–seropositive
patients received prophylactic acyclovir following their sec-
ond HSCT, the time to acquire T-lymphocyte proliferative
responses to herpes virus would be expected to be delayed.
The kinetics of cellular reconstitution after a second HSCT
did not differ from that seen following a ﬁrst HSCT.
Kapoor et al. have previously shown that unrelated HSCT
recipients and a significant proportion of histocompatible
Figure 3. X-ray from patient UPN 188. Six years following her second
HSCT, this patient developed pain and swelling. The arrow indicates the
osteosarcoma at the right distal femur. The osteosarcoma was most likely
the result of the radiation therapy she received for her second HSCT.
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HSCT recipients have prolonged defects in their capacity to
produce antibodies to bacterial carbohydrate antigens [24].
In the present series, only 3 patients, all of whom received
histocompatible HSCT, developed normal PRP responses
following their second HSCT. Therefore, the recipients of
second HSCTs, like all HSCT recipients, need to be rou-
tinely monitored for their immune reconstitution and should
remain on prophylactic antibiotics and IVIG until adequate
anticarbohydrate antibody function is present.
Chemotherapy, irradiation, GVHD, and infection may
all contribute to long-term toxicities (endocrine, skeletal,
and neurocognitive) in recipients of HSCT. Recipients of a
second HSCT might be at an increased risk of endocrine
complications (impaired growth, ovarian or testicular dys-
function, abnormal pubertal progression, hypothyroidism,
and panhypopituitarism) because they have received multi-
ple agents that can affect the hypothalamic/pituitary axis,
thyroid gland, and gonads (TBI, MTX, and steroids)
[25,26]. In our series, 4 patients had multiple endo-
crinopathies (GH, gonad, thyroid, and diabetes). The pres-
ence of multiple endocrinopathies in 4 of our patients leads
us to suspect that recipients of 2 HSCTs are at increased risk
of developing multiple endocrinopathies compared to recip-
ients of a single HSCT.
Gonadal dysfunction in pediatric transplantation patients
is thought to be rarer than in adult patients because prepu-
bertal gonads are quiescent. However, many pediatric
patients treated with chemotherapy show evidence of hor-
monal dysfunction as they mature. Sanders et al. reported
that patients who have received HSCT with either high-dose
cyclophosphamide or TBI-based regimens are at increased
risk of gonadal dysfunction [25]. In our series, 11 patients
were studied for gonadal dysfunction; 2 patients had ovarian
dysfunction, and 1 had testicular dysfunction. These results
should be interpreted with some caution because many of the
surviving patients were young and prepubescent. As the age
of the survivors increases, the frequency of gonadal dysfunc-
tion may increase.
Children who receive a signiﬁcant amount of irradiation
are at risk of developing thyroid dysfunction. Approximately
10% of childhood ALL survivors who received both chemo-
therapy and 18 to 24 cGy of craniospinal irradiation develop
hypothyroidism [27]. Because the TBI dose used for HSCT
was 12 cGy, most of our second-HSCT recipients retained
relatively normal thyroid function.
Young children who receive irradiation are known to be
at risk for hypoplasia of their developing teeth [28,29].
Patients who are not HSCT recipients and are treated with
chemotherapy alone do not appear to have severe dental
complications. A review of more than 700 patients who
received a single HSCT at the Childrens Hospital Los Ange-
les identiﬁed only a single patient who had absent secondary
teeth; the patient had infantile ALL and had received cranial
irradiation at 2 years of age prior to HSCT. In the present
series, 3 patients who received second HSCT developed
signiﬁcant dental abnormalities. Two patients (UPN 188 and
411) received their ﬁrst HSCT during infancy (<12 months),
whereas the third patient (UPN 214) received his ﬁrst HSCT
at 3 years of age (Figure 3). Although cranial irradiation
seems to be the strongest factor related to dental abnormali-
ties, 1 of our patients (UPN 411) with significant dental
abnormalities did not receive cranial irradiation during either
HSCT, suggesting that children who receive 2 HSCT should
be followed closely for abnormal dental development.
The majority of previous studies have shown that HSCT
has a negative impact on neurocognitive function [30,31]. In
some studies there has been no significant decline in neu-
rocognitive functioning 1 to 3 years following HSCT [32].
We studied the impact of 2 HSCTs on neurocognitive func-
tion. Although the raw neurocognitive test scores show
decreased neurocognitive function, there were no statistically
significant differences when the pre–first-HSCT and the
post–second-HSCT (1-3 years) results were compared. With
longer follow-up, however, deﬁnable differences may be seen.
Of all of the possible late effects of chemoradiotherapy,
the risk of developing a second cancer is one of the most
severe. An estimated 3% to 12% of children treated for can-
cer will develop a secondary malignancy within 20 years
from their first diagnosis. Exposures to radiation therapy
and chemotherapy (mainly alkylating agents) are known risk
factors for developing secondary cancers. In our cohort,
only 1 patient developed a secondary cancer, an osteosar-
coma 6 years post–second HSCT. However, the number of
long-term survivors is low, and patients must continue to be
monitored for the development of secondary malignancies.
In conclusion, second HSCT can be successfully per-
formed for selected pediatric patients who suffer relapse or
graft failure following their initial HSCT. The major causes
of mortality continue to be relapse and infection. Although
there are long-term complications following a single HSCT,
some of these complications appear to be more severe fol-
lowing 2 HSCT (abnormal dental development and multi-
ple endocrinopathies). Younger patients are susceptible to
unique toxicities that differ from those occurring in adult
patients and need to be longitudinally evaluated for these
complications.
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